Life Science Conference 2019
EVENT DATE: 15 May 2019 - 17 May 2019
On Wednesday 15th – Friday 17th May, Price Forbes will be holding a Life Science Conference at the Macdonald Berystede Hotel and Spa in Ascot.
This conference is suitable for professionals working in the pharmaceutical industry looking to stay one step ahead of the political, legal and insurance landscape of life science and healthcare.
Guests will be welcomed with a three course dinner from 7pm on Wednesday 15th May. Throughout the event, guests can expect presentations on a range of topics including:
- Future regulatory and political landscape
- Legal environment in the US and EU
- Relevance of insurance to the changing world
- Cyber insurability and coverage vagueness/gaps/duplication
- Regulatory cover including warning letters
- Clinical trials – latest trends and approaches
- Product liability
- Risk financing strategy
Key speakers include:
Adam Grossman Vice President of Modelling and Senior Scientist at Praedicat
Adam develops Praedicat’s quantitative risk models for the insurance industry and leads Praedicat’s development of Life Science analytics and risk models.
Alexander Das Portfolio Manager Life Sciences at QBE
Alex began his liability insurance career in 1993 with Iron Trades Insurance Company until its acquisition by QBE in 2000, he rejoined QBE in 2015 following stints with Gerling Konzern Allgemeine and Newline Underwriting Management. Alex currently oversees the underwriting strategy and performance of QBE European Operations’ UK and international Lifescience liability book written from London and its overseas offices.
Catherine Geyman Director at Intersys
Catherine advises biopharmaceutical companies on quantifying and managing supply chain risks. She has led the development of SCAIR®, a pharma-centric supply chain risk analysis tool and monitors disruption data and trends across the Life Science sector.
Daniel Kracov Partner at Arnold & Porter
Daniel co-chairs the firm’s Life Science & Healthcare practice; he helps large manufacturing companies, trade associations and early-stage ventures negotiate challenges relating to the development, manufacturing, approval and promotion of drugs, biologics, medical devices and diagnostics.
Edward Allera Co-chair of Buchanan Ingersoll & Rooney FDA group
Ed counsels clients on new product development and business opportunities in the areas of pharmaceuticals, hi-tech products, medical devices, food and cosmetics.
Erica Constance Cyber Portfolio Manager at QBE
Erica leads the development and delivery of QBE’s strategy for cyber across the European Operations, showcasing QBE’s solutions orientated approach. Erica’s remit includes ensuring that QBE’s proposition keeps pace with the rapidly evolving Cyber risk environment and that QBE remain relevant to customers and brokers.
Ian Dodds-Smith Head of Arnold & Porter’s European Product Liability practice
Ian is also Co-Head of the Food, Drug and Medical Device practice where he has primary responsibility for the European Union market. He advises companies and trade associations on all aspects of the regulatory framework within Europe.
Jeffrey Horowitz Partner at Arnold & Porter
Jeff is an experienced trial lawyer who has represented a wide range of clients in complex litigation and government investigations. His diverse practice includes major product liability, intellectual property and qui tam matters, as well as internal investigations, regulatory and compliance counseling and litigation avoidance counseling.
Jenny Yu Senior Underwriter at Munich Re
Jenny heads up a Life Science team specialising in providing bespoke and new risk solutions for the Pharma, Biotech and Medical Device companies. She has provided solutions for small, medium and large companies in North America and Europe.
Kerry Weems CEO of Mycroft Bioanalytics and Executive Chairman of the value-based HealthCare Investors Alliance
Kerry works with clients and members to promote and implement value-based reimbursement and pricing for pharmaceuticals, devices, insurance, and health services.
Lee Farrow EVP and Life Sciences Industry Practice Leader at Chubb
Lee oversees the strategy, operations, and underwriting of biotechnology, pharmaceutical, supplement and medical device companies, service companies, and human clinical trials. During 24 years in the insurance industry he has had roles ranging from claims to in house counsel to underwriting.
Petra Mates Underwriter for EQuIP Pharma Non-Damage BI at Munich Re
Petra is a member of the Life Science practice within Munich Re’s New Risk Solutions team. She provides bespoke cover for own and supplier sites of Pharma, Biopharma, Medical Device and CDMO company.
Peter Tillmans Head of Liability Underwriting Specialities and Head of Financial Lines Underwriting at HDI Global SE
Peter has responsibility for large Pharma and Hospitals as well as other Business and 30 years of Liability Underwriting know-how.
Further speakers will be announced over the coming weeks.
The event will conclude at 12.30pm on Friday 17th May and is set to be a key date in the calendar of: insurers, brokers and risk/insurance managers working within the pharmaceutical industry.